The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2015 Dec 4

PMID 26630954

Citations 16

Authors

Won Je Jeon

Brian Dean

Elizabeth Scarr

Andrew Gibbons

Affiliations

Soon will be listed here.

Abstract

The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.

Citing Articles

Influence of Anticholinesterase Drugs on Activity and Properties of Na,K-ATPase in Rat Erythrocytes under Stress Caused by Intense Physical Exercise.

Dubrovskii V, Maslakova K, Savchenko E Bull Exp Biol Med. 2024; 177(4):427-430.

PMID: 39259465 DOI: 10.1007/s10517-024-06202-z.

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

Wong T, Li G, Li S, Gao W, Chen G, Gan S Signal Transduct Target Ther. 2023; 8(1):177.

PMID: 37137892 PMC: 10154768. DOI: 10.1038/s41392-023-01427-2.

Moderate Folic Acid Supplementation in Pregnant Mice Results in Altered Sex-Specific Gene Expression in Brain of Young Mice and Embryos.

Luan Y, Cosin-Tomas M, Leclerc D, Malysheva O, Caudill M, Rozen R Nutrients. 2022; 14(5).

PMID: 35268026 PMC: 8912750. DOI: 10.3390/nu14051051.

Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex.

Nabulsi L, Farrell J, McPhilemy G, Kilmartin L, Dauvermann M, Akudjedu T Neuropsychopharmacology. 2022; 47(9):1643-1651.

PMID: 35046509 PMC: 9283431. DOI: 10.1038/s41386-022-01268-7.

NRM 2021 Abstract Booklet.

J Cereb Blood Flow Metab. 2021; 41(1_suppl):11-309.

PMID: 34905986 PMC: 8851538. DOI: 10.1177/0271678X211061050.

References

Maier W, Buller R, Philipp M, Heuser I . The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988; 14(1):61-8. DOI: 10.1016/0165-0327(88)90072-9. View

Joubert J, Joubert P . Chorea and psychiatric changes in organophosphate poisoning. A report of 2 further cases. S Afr Med J. 1988; 74(1):32-4. View

Fava M . Weight gain and antidepressants. J Clin Psychiatry. 2000; 61 Suppl 11:37-41. View

Sullivan P, Neale M, Kendler K . Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000; 157(10):1552-62. DOI: 10.1176/appi.ajp.157.10.1552. View

Meier M, King G . Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med. 2000; 5(3):173-85. DOI: 10.1177/1358836X0000500307. View

Austin M, Mitchell P, Goodwin G . Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry. 2001; 178:200-6. DOI: 10.1192/bjp.178.3.200. View

Chau D, Rada P, Kosloff R, Taylor J, Hoebel B . Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. Neuroscience. 2001; 104(3):791-8. DOI: 10.1016/s0306-4522(01)00133-6. View

Lai M, Lai O, Keene J, Esiri M, Francis P, Hope T . Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001; 57(5):805-11. DOI: 10.1212/wnl.57.5.805. View

Zhang W, Basile A, Gomeza J, Volpicelli L, Levey A, Wess J . Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci. 2002; 22(5):1709-17. PMC: 6758851. View

10.

Mavissakalian M, Perel J, Guo S . Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol. 2002; 22(2):155-61. DOI: 10.1097/00004714-200204000-00008. View

11.

Porter A, Bymaster F, DeLapp N, Yamada M, Wess J, Hamilton S . M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res. 2002; 944(1-2):82-9. DOI: 10.1016/s0006-8993(02)02721-x. View

12.

Comings D, Wu S, Rostamkhani M, McGue M, Iacono W, MacMurray J . Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet. 2002; 114(5):527-9. DOI: 10.1002/ajmg.10406. View

13.

Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E . Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002; 7(10):1083-91. DOI: 10.1038/sj.mp.4001199. View

14.

McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A . The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003; 60(5):497-502. DOI: 10.1001/archpsyc.60.5.497. View

15.

El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M . Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A. 2003; 100(10):6227-32. PMC: 156354. DOI: 10.1073/pnas.1034823100. View

16.

Kessler R, Berglund P, Demler O, Jin R, Koretz D, Merikangas K . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. DOI: 10.1001/jama.289.23.3095. View

17.

Tzavara E, Bymaster F, Felder C, Wade M, Gomeza J, Wess J . Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry. 2003; 8(7):673-9. DOI: 10.1038/sj.mp.4001270. View

18.

Misra A, Ganesh S, Shahiwala A, Shah S . Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003; 6(2):252-73. View

19.

Zavitsanou K, Katerina Z, Katsifis A, Andrew K, Mattner F, Filomena M . Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology. 2003; 29(3):619-25. DOI: 10.1038/sj.npp.1300367. View

20.

Wang J, Hinrichs A, Stock H, Budde J, Allen R, Bertelsen S . Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 2004; 13(17):1903-11. DOI: 10.1093/hmg/ddh194. View